Reldesemtiv

DB15256InvestigationalSmall molecule

Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).

Chemical structure of Reldesemtiv
Formula / weight
C19H18F2N6O · 384.391 g/mol (avg)
Also known as
CK-2127107 · CK2127107

Resolves to

Compound
UNII4S0HBYW6QECAS1345410-31-2ChEMBLCHEMBL4297600
Structure
InChIKeyMQXWPWOCXGARRK-HJGJAMNPSA-NSMILESNC(=O)C1=CN(C=C1)C1=CN=C(NC[C@@]2(C[C@H](F)C2)C2=NC=CC=C2F)N=C1
Targets
P02585TNNC2

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Reldesemtiv, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In